Navigation Links
Extraordinary Shareholders' Meeting of Cytos Biotechnology Ltd: Shareholders Approve All Resolutions

ZURICH, November 4, 2013 /PRNewswire/ --

Cytos Biotechnology Ltd (SIX:CYTN) today announced that its shareholders have approved all resolutions at the Extraordinary Shareholders' Meeting the announced capital increase in particular.

The Extraordinary Shareholders' Meeting of Cytos Biotechnology Ltd took place at the company's headquarters in Schlieren (Zurich), Switzerland. It was attended by 28 shareholders. 12,673,384 shares or 56.55% of a total of 22,411,431 shares were represented.

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of targeted immuno-therapies. The Company's lead product candidate CYT003 is a novel, first-in-class, immune modulator in Phase 2 clinical development as a potential new treatment for asthma. CYT003 has a novel mechanism of action that inhibits the immune response that causes asthma, and may therefore be beneficial for the control of asthma. In a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function in patients with persistent allergic asthma, despite withdrawal of standard therapy with inhaled corticosteroids. CYT003 has been shown to have a good safety and tolerability profile in more than 450 individuals receiving the active agent so far. Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements  This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, including that CYT003 may not demonstrate safety or efficacy in clinical trials, that there may be delays in development or that CYT003 may not receive marketing approval, and that the Company relies on outside financing to meet capital requirements, which may not be available under acceptable terms or at all. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

SOURCE Cytos Biotechnology Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. How Companies Can Provide Extraordinary New B2B Products with Extraordinary Product Launches - A Sales Momentum White Paper
2. 3SBio Inc. Adjourns Extraordinary General Meeting of Shareholders
3. Leading Technology Incubator Honors Extraordinary Entrepreneurs
4. Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty
5. Adamis Pharmaceuticals CEO Provides Update for Shareholders
6. Hadasit Bio-Holdings CEO Letter to Shareholders
7. Medifirst Solutions, Inc. Announces Further Update To Shareholders
8. Letter from Alliqua CEO, Dave Johnston, to Shareholders
9. Amarantus BioSciences Issues CEO Letter to Shareholders
10. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
11. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from Austria, Hungary, ... be a new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has ... it now. , Biomarkers are components in the blood, tissue or body ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
(Date:5/12/2016)... 2016 , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
Breaking Biology News(10 mins):